![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/immunovant-postpones-batoclimab-readouts-maps-path-forward-for-second-fcrn-drug/
https://www.globenewswire.com/news-release/2024/05/29/2890254/0/en/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Fourth-Quarter-and-Fiscal-Year-Ended-March-31-2024.html
https://finance.yahoo.com/news/makes-immunovant-imvt-buy-stock-160011468.html
https://www.globenewswire.com//news-release/2024/03/12/2844418/0/en/Immunovant-Awarded-U-S-Patent-for-IMVT-1402.html
https://www.globenewswire.com//news-release/2024/02/12/2827408/0/en/Immunovant-Reports-Financial-Results-and-Provides-Corporate-Updates-for-the-Quarter-Ended-December-31-2023.html
https://www.globenewswire.com//news-release/2024/01/03/2803253/0/en/Immunovant-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.fiercebiotech.com/biotech/immunovant-stakes-claim-fcrn-niche-posting-midphase-graves-data-and-plotting-next-steps
https://endpts.com/immunovant-unveils-positive-early-data-for-phii-graves-disease-drug/
https://www.globenewswire.com//news-release/2023/12/20/2799661/0/en/Immunovant-Reports-Positive-Initial-Phase-2-Results-for-Batoclimab-in-Graves-Disease.html
https://www.globenewswire.com//news-release/2023/11/28/2786806/0/en/Immunovant-Announces-Positive-IMVT-1402-Initial-600-mg-MAD-Results-that-Confirm-Best-in-Class-Potential.html